Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,840 matching trials from the live ClinicalTrials.gov search.
Conditions
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Interventions
OTS167PO
Drug
Lead sponsor
OncoTherapy Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Norwalk, Connecticut • Atlanta, Georgia • Honolulu, Hawaii + 4 more
Conditions
Breast Neoplasms, Neoplasms, Hormone-dependent
Interventions
atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy
Drug · Procedure
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
17
States / cities
Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more
Conditions
Breast Cancer
Interventions
TAS-108
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Conditions
Breast Cancer
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Stanford, California • Boston, Massachusetts • New York, New York + 2 more
Conditions
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
Interventions
MQ719, Pembrolizumab
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Ipilimumab, Pembrolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Locally Advanced Metastatic BRAF Mutant Melanoma
Interventions
LEE011, LGX818
Drug
Lead sponsor
Array BioPharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Aurora, Colorado • Detroit, Michigan • New York, New York + 2 more
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib, Capivasertib, Abemaciclib
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Phoenix, Arizona • Springdale, Arkansas + 30 more
Conditions
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, incomplete Freund's adjuvant, telomerase: 540-548 peptide vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma (Skin)
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
Capecitabine, Exisulind
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
87
States / cities
Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
32
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more
Conditions
Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
21
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 14 more
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Head and Neck Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Melanoma (Skin)
Interventions
aldesleukin, staphylococcal enterotoxin B
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Breast Cancer
Interventions
Radioiodide (131I-)
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Metastatic Breast Cancer
Interventions
Patients and Caregivers Qualitative Interview
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Breast Cancer
Interventions
Neratinib, T-DM1
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
15
States / cities
Weston, Florida • Decatur, Illinois • Effingham, Illinois + 7 more
Conditions
Breast Cancer
Interventions
Carboplatin, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Stamford, Connecticut • Bangor, Maine • Boston, Massachusetts + 5 more
Conditions
Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions
LMB-2 immunotoxin, MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland